Abstract
Neoadjuvant endocrine therapy (NET) is indicated for treatment of invasive breast carcinomas of luminal subtypes (RH+/HER2-) in locally advanced stages. Several previous randomized studies have shown the benefit of aromatase inhibitors (AI) in this context. However, in care practice, NET has been reserved for cases of elderly or frail patients, where neoadjuvant chemotherapy (NAC) would b…